Manja Bouman

Kiadis BV is a drug discovery and development company with a focus on oncology and metabolic disorders. Kiadis has developed a proprietary technology platform, BioSelact technology that is used to perform drug discovery screening programs using natural extracts as well as synthetic mixtures and with the key advantage of direct identification and dereplication of the active compounds present in extracts or mixtures. The company is headquartered in Groningen, the Netherlands.

Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands.

Part of Thermo Fisher Scientific, Inc., DSM Pharmaceutical Products, Inc. is a science-based company that specializes in nutrition, health, and bioscience. The company is based in Parsippany, NJ. The company offers solutions for animal nutrition, human nutrition and care, food and beverage, and materials. DSM's companies cover a range of human and animal health and nutrition businesses. DSM's investor relations team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts.

Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.